PBMS-IMRT对降低同步放化疗盆腔肿瘤患者血液不良反应研究的新进展

doi:10.3760/cma.j.issn.1004-4221.2018.10.017

摘要
图/表
参考文献()
相关文章 (2)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要

对晚期盆腔肿瘤患者采用同步放化疗可以提高其生存率,但血液等不良反应明显增多,常导致患者不能耐受而中断治疗。限定盆骨骨髓调强放疗(PBMS-IMRT)在降低盆骨骨髓照射剂量和体积方面具有明显优势,本文就PBMS-IMRT与其他照射方式的比较、放疗剂量学参数与血液不良反应的相关性以及勾画精确活性骨髓的影像学方法进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄今
	李光

关键词 ：盆腔肿瘤/限定盆骨骨髓调强放射疗法, 血液不良反应, 剂量学参数

Abstract：

oncurrent chemoradiotherapy can improve the survival rate in patients with advanced pelvic tumors. However, it also increases the incidence of hematologic toxicity and other adverse events. Patients cannot tolerate these adverse events and discontinue the therapy. Pelvic bone marrow-sparing intensity-modulated radiotherapy (PBMS-IMRT) possesses obvious advantages in reducing the radiation dose and volume of the pelvic bone marrow. In this article, comparison between PBMS-IMRT and other irradiation therapies, correlation between dosimetric parameters and hematologic toxicity and imaging Methods with precise delineation of the active bone marrow were reviewed.

Key words： Pelvic neoplasm/pelvic bone marrow-sparing intensity-modulated radiotherapy Hematologic toxicity Dosimetric parameters

收稿日期: 2017-09-03

通讯作者: 李光,Email: 13804058616@163.com

引用本文:

黄今,李光. PBMS-IMRT对降低同步放化疗盆腔肿瘤患者血液不良反应研究的新进展[J]. 中华放射肿瘤学杂志, 2018, 27(10): 949-951.

Huang Jin,Li Guang. Research progress in effect of pelvic bone marrow-sparing intensity-modulated radiotherapy on hematologic toxicity in pelvic tumor patients after concurrent chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2018, 27(10): 949-951.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.10.017 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I10/949

[1] Kachnic LA,Winter K,Myerson RJ,et al. RTOG 0529:a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal[J].Int J Radiat Oncol Biol Phys,2013,86(1):27-33.DOI:10.1016/j.ijrobp.2012.09.023.
[2] Kurotaki D,Uede T,Tamura T.Functions and development of red pulp macrophages[J].Microbiol Immunol,2015,59(2):55-62.DOI:10.1111/1348-0421.12228.
[3] Omatsu Y.The niche for hematopoietic stem and progenitor cells in bone marrow[J].Clin Calcium,2016,26(5):671-6.DOI:CliCa1605671676.
[4] Sini C,Fiorino C,Perna L,et al. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancerradiotherapy with pelvic node irradiation[J].Radiother Oncol,2016,118(1):79-84.DOI:10.1016/j.radonc.2015.11.020.
[5] Toussaint O,Medrano EE,von Zglinicki T.Cellular and molecular mechanisms of stress-induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes[J].Exp Gerontol,2000,35(8):927-945.
[6] Cruet-Hennequart S,Drougard C,Shaw G,et al. Radiation-induced alterations of osteogenic and chondrogenic differentiation of human mesenchymal stemcells[J/OL].PLoS One,2015,10(3):e0119334.DOI:10.1371/journal.pone.0119334.
[7] Damek-Poprawa M,Stefanik D,Levin LM,et al. Human bone marrow stromal cells display variable anatomic site-dependent response and recovery from irradiation[J].Arch Oral Biol,2010,55(5):358-64.DOI:10.1016/j.archoralbio.2010.03.010.
[8] Wan J,Liu K,Li K,et al. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?[J].Radiat Oncol,2015,10:162.DOI:10.1186/s13014-015-0454-0.
[9] Mell LK,Tiryaki H,Ahn KH,et al. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer[J].Int J Radiat Oncol Biol Phys,2008,71(5):1504-1510.DOI:10.1016/j.ijrobp.2008.04.046.
[10] Wan J,Liu K,Li K,et al. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy[J].Radiat Oncol,2015,10:162.DOI:10.1186/s13014-015-0454-0.
[11] Platta CS,Bayliss A,Mchaffie D,et al. A dosimetric analysis of tomotherapy based intensity modulated radiation therapy with and without bone marrow sparing in gynecologic malignancies[J].Technol Cancer Res Treat,2013,12(1):19-29.
[12] Roeske JC,Lujan A,Rotmensch J,et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies[J].Int J Radiat Oncol Biol Phys,2000,48(5):1613-1621.
[13] Zhu H,Zakeri K,Vaida F,et al. Longitudinal study of acute haematologic toxicity in cervical cancer patients treated with chemoradiotherapy[J].J Med Imaging Radiat Oncol,2015,59(3):386-393.DOI:10.1111/1754-9485.12297.
[14] Mell LK,Kochanski JD,Roeske JC,et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy[J].Int J Radiat Oncol Biol Phys,2006,66(5):1356-1365.
[15] Rose BS,Aydogan B,Liang Y,et al. Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patient streated with chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2011,79(3):800-7.DOI:10.1016/j.ijrobp.2009.11.010.
[16] Albuquerque K,Giangreco D,Morrison C,et al. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT[J].Int J Radiat Oncol Biol Phys,2011,79(4):1043-7.DOI:10.1016/j.ijrobp.2009.12.025.
[17] Klopp A,Moughan J,Portelance H,et al. Hematologic toxicity in RTOG 0418:a phase 2 study of postoperative IMRT for gynecologic cancer[J].Int J Radiat Oncol Biol Phys,2013,86(1):83-90.DOI:10.1016/j.ijrobp.2013.01.017.
[18] Jianyang W,Yuan T,Yuan T,et al. A prospective phase Ⅱ study of magnetic resonance imaging guided hematopoietical bone marrow-sparingintensity-modulated radiotherapy with concurrent chemotherapy for rectal cancer[J].Radiol Med,2016,121(4):308-14.DOI:10.1007/s11547-015-0605-2.
[19] Mahantshetty U,Krishnatry R,Chaudhari S,et al. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer[J].Int JGynecol Cancer,2012,22(8):1427-1434.
[20] Bazan JG,Luxton G,Mok EC.Normal tissue complication probability modeling of acute hematologic toxicity in patients treated within tensity-modulated radiation therapy for squamous cell carcinoma of the anal canal[J].Int J Radiat Oncol Biol Phys,2012,84(3):700-6.DOI:10.1016/j.ijrobp.2011.12.072.
[21] Sini C,Fiorino C,Perna L,et al. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation[J].Radiother Oncol,2016,118(1):79-84.DOI:10.1016/j.radonc.2015.11.020.
[22] Liang Y,Messer K,Rose BS,et al. Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer:principal component analysis on high dimensional data[J].Int J Radiat Oncol Biol Phys,2010,78(3):912-9.DOI:10.1016/j.ijrobp.2009.11.062.
[23] Rose BS,Jee KW,Niemierko A,et al. Irradiation of FDG-PET-defined active bone marrow subregions and acute hematologic toxicity in anal cancer patients undergoing chemoradiation[J].Int J Radiat Oncol Biol Phys,2016,94(4):747-54.DOI:10.1016/j.ijrobp.2015.12.006.
[24] McGuire SM,Menda Y,Boles-Ponto LL,et al. Spatial mapping of functional pelvic bone marrow using FLT PET[J].J Appl Clin Med Phys,2014,15(4):129-136.DOI:10.1120/jacmp.v15i4.4780.
[25] McGuire SMBhatia SK,Sun W,et al. Using^{[(18) F]}fluorothymidine imaged with positron emission tomography to quantify and reduce hematologic toxicity due to chemoradiation therapy for pelvic cancer patients[J].Int J Radiat Oncol Biol Phys,2016,96(1):228-239.DOI:10.1016/j.ijrobp.2016.04.009.
[26] ÖzgenA.Comparison of fat-saturated T2-weighted and contrast-enhanced fat-saturated T1-weighted sequences in MR imaging of sacroiliac joints in diagnosing active sacroiliitis[J].Eur J Radiol,2015,84(12):2593-6.DOI:10.1016/j.ejrad.2015.08.021.